Biocon Confident As First Biosimilars Seen Hitting Europe In Early 2018

Oct 24 2016

• By Penelope MacRae

Listen to this article

India’s leading biologics company Biocon has said it expects its first biosimilar products to be launched in the European market by early 2018 and is bullish on both its plans in the sector and earnings prospects after reporting quarterly net profit soared by a better than expected 52%.

India_moneybox_1200x675

For years, shares of Bangalore-based Biocon Ltd., Asia’s largest biopharmaceutical company and the fourth-largest insulin manufacturer in the world, underperformed their Indian drug company peers. But now analysts say the tide is turning and the company’s stock price has more than doubled in the past 12 months, as investors expect a strong performance from Biocon’s portfolio of biosimilars.

“What we’re betting on big is our biosimilars business and that’s something where we’re seeing a lot of good uptake...

More from India

How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA
Oct 16 2025
Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.
GenAI Reality In Pharma Amid Hype, Advances In LLMs For Therapeutics
Aug 27 2024
• By Anju Ghangurde
Indegene’s CTO talks to Scrip about the state of GenAI implementations in pharma amid hype and limited clarity on ROI, the need to address foundational issues early on, promising pilots, the firm’s alliance with Microsoft and Google’s generalist LLM for therapeutics.
With Mpox Vaccine In Serum Institute Pipeline, What Could Favor India Vaccine Makers?
Aug 22 2024
• By Vibha Ravi
Serum Institute is working on an mpox vaccine while other Indian firms are weighing options after the WHO sounded an alert and a new case was reported in neighboring Pakistan. Scrip looks at factors that could favor development and/or manufacture of an mpox vaccine at Indian majors.
Glenmark Chief On ‘Big Shift’ In Revenue By Region, Liraglutide India Outlook
Aug 21 2024
• By Anju Ghangurde
Momentum in Europe may see the region’s contribution to Glenmark’s revenues become almost as big as the US business, currently dented by multiple challenges. The firm also outlines how things are poised in India for its biosimilar to Novo Nordisk’s Victoza.

More from Focus On Asia

India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2
Oct 14 2025
A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.
Innovent/GenFleet Score China’s First KRAS G12C Inhibitor Approval
Mar 10 2025
• By Dexter Jie Yan
The nod will help unlock a national market for the partners’ Dupert (fulzerasib) in which roughly 50,000 people are expected to be newly diagnosed with lung cancer harboring the KRAS G12C mutation in 2025. Meanwhile, two other homegrown rivals are also closing in on marketing clearances in China.
As More DLL3 Bispecifics Advance, Doctors Are Adjusting To CRS, ICANS
Mar 10 2025
• By Mandy Jackson
Amgen’s Imdelltra for small-cell lung cancer is one of two bispecific T-cell engagers approved for solid tumors, but data at the WCLC meeting show other DLL3-targeting BiTEs may be on the way.